Share

Pfizer has reported positive 26-week data from the ongoing Phase III REFLECTIONS B328-06 trial evaluating the safety and efficacy of PF-05280586 in comparison with rituxan / mabthera (rituximab-EU) for the first-line treatment of patients with CD20-positive, low tumour burden, follicular lymphoma.

The 26-week data showed that the trial met its primary endpoint of overall response rate (ORR).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It showed no clinically meaningful differences in efficacy between PF-05280586 and mabthera among the 394 enrolled patients.

ORR was reported to be 75.5% at 26 weeks in patients treated with PF-05280586 against 70.7% in patients receiving rituximab.

The estimated rates of one-year progression-free survival were reportedly consistent across the PF-05280586 and mabthera groups.

“The data presented today will help us understand the nuances of the medicine without the confounding influence of additional concurrent treatments.”

Results demonstrated that both PF-05280586 and mabthera had a similar safety profile.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

US Oncology Hematology Research medical director Dr Jeff Sharman said: “It is encouraging to see new data supporting a potential rituximab biosimilar.

“If approved this may help provide a more cost-effective treatment option and expand access for patients and physicians.

“The data presented today will help us understand the nuances of the medicine without the confounding influence of additional concurrent treatments.”

The REFLECTIONS B328-06 study comprises a randomised, 52-week double-blind clinical trial design that aims to assess the efficacy, safety and immunogenicity, pharmacokinetics and pharmodynamics of PF-05280586 against mabthera.

PF-05280586 is an investigational monoclonal antibody (mAb) that is being developed as a potential biosimilar to rituxan / mabthera.